FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922415295> ?p ?o ?g. }

• W2922415295 endingPage "181" @default.
• W2922415295 startingPage "167" @default.
• W2922415295 abstract "Platinum-based chemotherapy remains the standard of care for most lung cancer cases. However chemoresistance is often developed during the treatment, limiting clinical utility of this drug. Recently, the ability of tumor cells to adapt their metabolism has been associated to resistance to therapies. In this study, we first described the metabolic reprogramming of Non-Small Cell Lung Cancer (NSCLC) in response to cisplatin treatment. Cisplatin-resistant versions of the A549, H1299, and H460 cell lines were generated by continuous drug exposure. The long-term metabolic changes, as well as, the early response to cisplatin treatment were analyzed in both, parental and cisplatin-resistant cell lines. In addition, four Patient-derived xenograft models treated with cisplatin along with paired pre- and post-treatment biopsies from patients were studied. Furthermore, metabolic targeting of these changes in cell lines was performed downregulating PGC-1α expression through siRNA or using OXPHOS inhibitors (metformin and rotenone). Two out of three cisplatin-resistant cell lines showed a stable increase in mitochondrial function, PGC1-α and mitochondrial mass with reduced glycolisis, that did not affect the cell cycle. This phenomenon was confirmed in vivo. Post-treatment NSCLC tumors showed an increase in mitochondrial mass, PGC-1α, and a decrease in the GAPDH/MT-CO1 ratio. In addition, we demonstrated how a ROS-mediated metabolism reprogramming, involving PGC-1α and increased mitochondrial mass, is induced during short-time cisplatin exposure. Moreover, we tested how cells with increased PGC-1a induced by ZLN005 treatment, showed reduced cisplatin-driven apoptosis. Remarkably, the long-term metabolic changes, as well as the metabolic reprogramming during short-time cisplatin exposure can be exploited as an Achilles' heel of NSCLC cells, as demonstrated by the increased sensitivity to PGC-1α interference or OXPHOS inhibition using metformin or rotenone. These results describe a new cisplatin resistance mechanism in NSCLC based on a metabolic reprogramming that is therapeutically exploitable through PGC-1α downregulation or OXPHOS inhibitors." @default.
• W2922415295 created "2019-03-22" @default.
• W2922415295 creator A5004476887 @default.
• W2922415295 creator A5010234932 @default.
• W2922415295 creator A5013422694 @default.
• W2922415295 creator A5018014202 @default.
• W2922415295 creator A5019884407 @default.
• W2922415295 creator A5021914242 @default.
• W2922415295 creator A5030590587 @default.
• W2922415295 creator A5034722786 @default.
• W2922415295 creator A5041909803 @default.
• W2922415295 creator A5044393978 @default.
• W2922415295 creator A5044504982 @default.
• W2922415295 creator A5048129952 @default.
• W2922415295 creator A5048713337 @default.
• W2922415295 creator A5053190947 @default.
• W2922415295 creator A5058913537 @default.
• W2922415295 creator A5060556575 @default.
• W2922415295 creator A5084315308 @default.
• W2922415295 creator A5085499011 @default.
• W2922415295 date "2019-05-01" @default.
• W2922415295 modified "2023-10-16" @default.
• W2922415295 title "Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition" @default.
• W2922415295 cites W1980684292 @default.
• W2922415295 cites W1986889886 @default.
• W2922415295 cites W1995103178 @default.
• W2922415295 cites W2013935749 @default.
• W2922415295 cites W2040608814 @default.
• W2922415295 cites W2044433516 @default.
• W2922415295 cites W2049376215 @default.
• W2922415295 cites W2052543023 @default.
• W2922415295 cites W2068119233 @default.
• W2922415295 cites W2069489023 @default.
• W2922415295 cites W2091673304 @default.
• W2922415295 cites W2096070852 @default.
• W2922415295 cites W2097259163 @default.
• W2922415295 cites W2102322990 @default.
• W2922415295 cites W2114090713 @default.
• W2922415295 cites W2117692326 @default.
• W2922415295 cites W2125408763 @default.
• W2922415295 cites W2125667072 @default.
• W2922415295 cites W2127875945 @default.
• W2922415295 cites W2131281949 @default.
• W2922415295 cites W2133367167 @default.
• W2922415295 cites W2133512940 @default.
• W2922415295 cites W2141037581 @default.
• W2922415295 cites W2150822910 @default.
• W2922415295 cites W2163351155 @default.
• W2922415295 cites W2173531900 @default.
• W2922415295 cites W2186118939 @default.
• W2922415295 cites W2188417988 @default.
• W2922415295 cites W2259656061 @default.
• W2922415295 cites W2273029502 @default.
• W2922415295 cites W2336359166 @default.
• W2922415295 cites W2410849341 @default.
• W2922415295 cites W2480725775 @default.
• W2922415295 cites W2519786994 @default.
• W2922415295 cites W2531423675 @default.
• W2922415295 cites W2549576025 @default.
• W2922415295 cites W2591269807 @default.
• W2922415295 cites W2736018139 @default.
• W2922415295 cites W2745896531 @default.
• W2922415295 cites W2770511988 @default.
• W2922415295 cites W4249552602 @default.
• W2922415295 doi "https://doi.org/10.1016/j.freeradbiomed.2019.03.009" @default.
• W2922415295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30880247" @default.
• W2922415295 hasPublicationYear "2019" @default.
• W2922415295 type Work @default.
• W2922415295 sameAs 2922415295 @default.
• W2922415295 citedByCount "98" @default.
• W2922415295 countsByYear W29224152952019 @default.
• W2922415295 countsByYear W29224152952020 @default.
• W2922415295 countsByYear W29224152952021 @default.
• W2922415295 countsByYear W29224152952022 @default.
• W2922415295 countsByYear W29224152952023 @default.
• W2922415295 crossrefType "journal-article" @default.
• W2922415295 hasAuthorship W2922415295A5004476887 @default.
• W2922415295 hasAuthorship W2922415295A5010234932 @default.
• W2922415295 hasAuthorship W2922415295A5013422694 @default.
• W2922415295 hasAuthorship W2922415295A5018014202 @default.
• W2922415295 hasAuthorship W2922415295A5019884407 @default.
• W2922415295 hasAuthorship W2922415295A5021914242 @default.
• W2922415295 hasAuthorship W2922415295A5030590587 @default.
• W2922415295 hasAuthorship W2922415295A5034722786 @default.
• W2922415295 hasAuthorship W2922415295A5041909803 @default.
• W2922415295 hasAuthorship W2922415295A5044393978 @default.
• W2922415295 hasAuthorship W2922415295A5044504982 @default.
• W2922415295 hasAuthorship W2922415295A5048129952 @default.
• W2922415295 hasAuthorship W2922415295A5048713337 @default.
• W2922415295 hasAuthorship W2922415295A5053190947 @default.
• W2922415295 hasAuthorship W2922415295A5058913537 @default.
• W2922415295 hasAuthorship W2922415295A5060556575 @default.
• W2922415295 hasAuthorship W2922415295A5084315308 @default.
• W2922415295 hasAuthorship W2922415295A5085499011 @default.
• W2922415295 hasBestOaLocation W29224152951 @default.
• W2922415295 hasConcept C126322002 @default.
• W2922415295 hasConcept C134018914 @default.
• W2922415295 hasConcept C143998085 @default.

• next